- Home
- RHE vs CHRO Comparison
RHE vs CHRO Comparison
Compare RHE & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHE
- CHRO
- Stock Information
- Founded
- RHE 1988
- CHRO 2002
- Country
- RHE United States
- CHRO United States
- Employees
- RHE N/A
- CHRO N/A
- Industry
- RHE Real Estate
- CHRO
- Sector
- RHE Real Estate
- CHRO
- Exchange
- RHE Nasdaq
- CHRO Nasdaq
- Market Cap
- RHE 3.5M
- CHRO 3.9M
- IPO Year
- RHE 2006
- CHRO 2024
- Fundamental
- Price
- RHE $1.57
- CHRO $0.66
- Analyst Decision
- RHE
- CHRO Strong Buy
- Analyst Count
- RHE 0
- CHRO 1
- Target Price
- RHE N/A
- CHRO N/A
- AVG Volume (30 Days)
- RHE 27.3K
- CHRO 100.6K
- Earning Date
- RHE 11-29-2024
- CHRO 11-13-2024
- Dividend Yield
- RHE N/A
- CHRO N/A
- EPS Growth
- RHE N/A
- CHRO N/A
- EPS
- RHE N/A
- CHRO N/A
- Revenue
- RHE $15,936,000.00
- CHRO N/A
- Revenue This Year
- RHE N/A
- CHRO N/A
- Revenue Next Year
- RHE N/A
- CHRO N/A
- P/E Ratio
- RHE N/A
- CHRO N/A
- Revenue Growth
- RHE N/A
- CHRO N/A
- 52 Week Low
- RHE $1.13
- CHRO $0.52
- 52 Week High
- RHE $3.08
- CHRO $6.00
- Technical
- Relative Strength Index (RSI)
- RHE 43.01
- CHRO 48.22
- Support Level
- RHE $1.13
- CHRO $0.63
- Resistance Level
- RHE $2.11
- CHRO $0.69
- Average True Range (ATR)
- RHE 0.15
- CHRO 0.06
- MACD
- RHE -0.04
- CHRO 0.01
- Stochastic Oscillator
- RHE 44.90
- CHRO 52.55
About RHE Regional Health Properties Inc.
Regional Health Properties Inc is a self-managed healthcare real estate investment company that invests in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions. It has two reportable segments real estate segment and the healthcare services segment. It derives the majority of its revenue from the healthcare services segment. Its portfolio of properties is diversified across various states, with concentrations in Georgia and Ohio.
About CHRO Chromocell Therapeutics Corporation
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.